Project Grant 2203330
Award Date
6/15/22
Completion Date
5/31/23
Dollars Obligated
$432K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Roanoke, VA 24016, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,990 aims to advance the regulatory pathway for commercializing space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The project, led by Eascra Biotech, Inc., a for-profit small business in Pawtucket, RI, focuses on demonstrating the comparability of space-manufactured JBNPs to earth-made counterparts. JBNPs offer...
Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Project Grant award of $275,000 provides funding to Illuminate Therapeutics, Inc. to develop their Light Activated Drug Delivery and Release (LADDR) platform technology. The objective is to improve patient outcomes in the treatment of head and neck and esophageal cancers, which represent a combined market of over $2.34B in 2021 growing at 10.5% annually. The key focus of this SBIR Phase...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Absco Therapeutics, Inc. aims to develop an image-guided intratumoral delivery system for biologic cancer immunotherapies. The project seeks to improve the localized retention, controlled release, and therapeutic efficacy of these biologics within solid tumors, addressing current limitations of rapid drug leakage and systemic toxicity. The anticipated outcomes...
This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023. The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo ineffective...
This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...